DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20220298

Study of seroprevalence of antibodies to SARS-COV-2 among the healthy blood donors of Jammu region

Neeti Dutt, Sushil Sharma, Meena Sidhu

Abstract


Background: SARS‑CoV‑2 emerged in China and spread throughout the world due to its rapid transmission. The exposure rate in the healthy population is unknown, mainly in resource‑limited countries. Herein, we estimated the seroprevalence of anti‑SARS‑CoV‑2 antibodies and risk factors among blood donors at our blood bank and to describe some characteristics of those that test positive. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV2 during the peak period of the COVID-19 pandemic in Jammu State, India to know the magnitude of SARS-CoV-2 exposure, the prevalence of herd immunity in the population.

Methods: This is prospective observational study of COVID-19 seroprevalence among blood donors that complied with blood donation protocol. Participation in study was voluntary after taking proper consent on the consent form.

Results: A total of 750 random blood donors who voluntarily participated, were enrolled in this study after obtaining their proper consent on the consent form. Out of 750 donors, 287 (38.2%) were positive for IgG antibodies and 463 (61.7%) were negative for IgG antibodies. In our study, male donors (745) outnumbered the female donors but on the other hand female donors showed a higher prevalence of covid antibodies i.e., 60% as compared to male donors i.e., 38% which is a statistically significant difference (p<0.005).

Conclusions: A high prevalence of SARS-CoV-2 antibodies was detected among blood donors which indicated a high level of exposure to the virus within the population and development of innate immunity against the virus. This could help us to introduce a protocol of antibody testing in the screening of blood donors to enhance the number of plasma donation cases for the treatment of serious COVID patients.


Keywords


SARS-CoV IgG antibodies, Blood donors, Seroprevalence, ABO blood groups

Full Text:

PDF

References


Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A novel corona‑ virus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020;382:1199-207.

World Health Organization. COVID‑19 Weekly Epidemiological Update. WHO. 2020. Available at: https://www.who.int/docs/default‑source/coronaviruse/situation‑reports/20201012‑weekly‑epi‑update‑9.pdf. Accessed on 10 June 2021.

Filho LA, Szwarcwald CL, Mateos S de OG, De Leon ACMP, De Andrade Medronho R, Veloso VG et al. Seroprevalence of anti‑SARS‑CoV‑2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica. 2020;54:1-10.

Wang P, Anderson N, Pan Y, Poon L, Charlton C, Zelyas N et al. The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception. Clin Chem. 2020;66(5):644-51.

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-4.

Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? J Clin Microbiol. 2020;29.

World Health Organization. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19). Interim guidance 2020. Available at: https://apps.who.it/iris/hadle/10665/331523.

Fontanet A, Tondeur L, Madec Y. Cluster of COVID-19 in northern France: A retrospective closed cohort study. Medrxiv 2020.

Younas A, Waheed S, Khawaja S, Imam M. Seroprevalence of SARS-CoV-2antibodies among healthy blooddonors in Karachi, Pakistan. Transfus Apheresis Sci. 2020;59:102923.

Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ et al. Sero‑ prevalence of antibodies to sars‑cov‑2 in 10 sites in the United States. JAMA Intern Med. 2020;180:1776-86.

Pollán M, Pérez‑Gómez B, Pastor‑Barriuso R, Oteo J, Hernán MA, Pérez‑ Olmeda M et al. Prevalence of SARS‑CoV‑2 in Spain (ENE‑COVID): a nationwide, population‑based sero-epidemiological study. Lancet. 2020;396:535-44.

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H et al. Seroprevalence of anti‑SARS‑CoV‑2 IgG antibodies in Geneva, Switzer‑ land (SEROCoV‑POP): a population‑based study. Lancet. 2020;396:313-9.

Xu X, Sun J, Nie S, Li H, Kong Y, Liang M. Seroprevalence of immunoglobulin M and G antibodies against SARS‑CoV‑2 in China. Nat Med. 2020;26:1193-5.

Filho LA, Szwarcwald CL, Mateos S de OG, de Leon ACMP, de Andrade Medronho R, Veloso VG et al. Seroprevalence of anti‑SARS‑CoV‑2 among blood donors in Rio de Janeiro, Brazil. Rev Saude Publica. 2020;54:1-10.

Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M et al. SARS‑ CoV‑2 seroprevalence trends in healthy blood donors during the COVID‑ 19 outbreak in Milan. Blood Transfus. 2021;19:181-9.

Erikstrup C, Hother CE, Pedersen OBV, Mølbak K, Skov RL, Holm DK et al. Estimation of SARS‑CoV‑2 infection fatality rate by real‑time antibody screening of blood donors. Clin Infect Dis. 2021;72:249-53.

Banjar A, Al‑Tawfiq JA, Alruwaily A, Alserehi H, Al‑Qunaibet A, Alaswad R et al. Seroprevalence of antibodies to SARS‑CoV‑2 among blood donors in the early months of the pandemic in Saudi Arabia. Int J Infect Dis. 2021;104:452-7.

Fischer B, Knabbe C, Vollmer T. SARS‑CoV‑2 IgG seroprevalence in blood donors located in three different federal states, Germany. Eurosurveillance. 2020;25:1-4.

Sykes W, Mhlanga L, Swanevelder R, Glatt TN, Grebe E, Coleman C et al. Prevalence of anti‑SARS‑CoV‑2 antibodies among blood donors in Northern Cape, KwaZulu‑Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. Res Sq. 2021;rs.3.rs-233375.

Channappanavar R, Fett C, Mack M. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017;198:4046-53.

Mahapatra S. SARS COV-2 IgG antibodies in blood donors in pandemic-A gamechanger for policy makers. Elsevier Masson. 2021;S1246-7820(21)00480-8.

Martinez-Acuña N, Avalos-Nolazco DM, Rodriguez-Rodriguez DR, Martinez-Liu CG, Galan-Huerta KA, Padilla-Rivas GR et al. Seroprevalence of Anti-SARS-CoV-2 Antibodies in Blood Donors from Nuevo Leon State, Mexico, during 2020: A Retrospective Cross-Sectional Evaluation. Viruses. 2021;13:1225.

Golinelli D, Boetto E, Maietti E, Fantini MP. The association between ABO blood group and SARS-CoV-2 infection: a meta-analysis. PLOS ONE. 2020;15:e0239508.

Nimgaonkar I, Valeri L, Susser E, Hussain S, Sunderram J, Aviv A. The age pattern of the male-to-female ratio in mortality from COVID-19 mirrors that of cardiovascular disease in the general population. Aging. 2021;13:3190-201.

Gupta S, Nakabo S, Blanco LP, O’Neil LJ, Wigerblad G, Goel RR et al. Sex differences in neutrophil biology modulate response to type I interferons and immunometabolism. Proc Natl Acad Sci USA. 2020;117:16481-491.

Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P et al. Seroprevalence of anti‑SARS‑CoV‑2 IgG antibodies in Kenyan blood donors. MedRxiv. 2020;82:79-82.

Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A et al. SARS‑CoV‑2 antibody seroprevalence in the general population and high‑risk occupational groups across 18 cities in Iran: a population‑based cross‑sectional study. Lancet Infect Dis. 2021;21:473-81.

Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X et al. Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID‑19) Susceptibility. Clin Infect Dis. 2020;1-35.

Jokela M, Virtanen M, David Batty G, Kivimaki M. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 2005;293:1447.

Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and risk of SARS‑CoV‑2 pneumonia. Br J Haematol. 2020;190:24-7.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O’Brien SF. SARS‑CoV‑2 seroprevalence among blood donors after the first COVID‑19 wave in Canada. Transfusion. 2021;61:862-72.

Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N et al. Higher SARS‑CoV‑2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS One. 2021;16:1-12.